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Background: Oocyte retrieval failure following an ovarian hyperstimulation protocol is uncommon in assisted
reproductive technology (ART) programs. We analyzed the predictive factors for oocyte retrieval failure following
controlled ovarian hyperstimulation (COH) with gonadotropin-releasing hormone (GnRH) agonist and GnRH
antagonist protocols in ART programs.
Methods: This study was a retrospective cohort observational study. In total, 744 cycles from 361 patients who
underwent controlled ovarian hyperstimulation with GnRH agonist long protocol or antagonist protocol were
analyzed. Treatment cycles with oocyte retrieval failure and with one or more oocytes retrieved were compared
to determine predictive factors for oocyte retrieval failure using univariate and multilevel multivariate logistic
regression analyses.
Results: Oocyte retrieval failure occurred in 38 cycles (5.1 %). The oocyte retrieval failure rate of the GnRH antagonist
protocol (8.1 %) was significantly higher than that of the GnRH agonist long protocol (3.7 %). On multilevel multivariate
logistic analysis, cycles with GnRH antagonist protocol (odds ratio [OR] 3.06, 95 % confidence interval [CI] 1.05–8.96),
estradiol level on the day of human chorionic gonadotropin (hCG) injection (OR 0.997, 95 % CI 0.996–0.998), and
luteinizing hormone (LH) level on the day of hCG injection (OR 1.19, 95 % CI 1.06–1.33) were independent predictive
factors for oocyte retrieval failure. The efficacy of estradiol and LH levels on the day of hCG injection for predicting
oocyte retrieval failure was evaluated using receiver operating characteristic curves. In all cycles, the areas under the
curve (AUCs) for estradiol and LH were 0.84 and 0.63, respectively, for all cycles; 0.84 and 0.52, respectively, for cycles
with GnRH agonist long protocol; and 0.81 and 0.82, respectively, for cycles with GnRH antagonist protocol.
Conclusions: Our results suggest that in cycles with GnRH antagonist protocol, the levels of estradiol and LH on
the day of hCG injection might be predictive factors for oocyte retrieval failure. This relationship may provide
useful information to both patients and physicians for developing better COH protocols in ART programs.
Keywords: Assisted reproductive technology, Oocyte retrieval, Empty follicle syndrome, Controlled ovarian
hyperstimulation, Gonadotropin-releasing hormone agonist, Gonadotropin-releasing hormone antagonistBackground
Assisted reproductive technology (ART) has been widely
used for infertility treatment [1]. Acquisition of oocytes is
the first step towards successful outcomes in an ART
program. Ovarian hyperstimulation with gonadotropin-* Correspondence: totakaha@med.id.yamagata-u.ac.jp
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protocols is used to maximize the number of retrieved
oocytes [2].
Oocyte retrieval failure, i.e., zero oocytes retrieved
following an ovarian hyperstimulation protocol, is uncom-
mon in ART programs [3] and referred to as “empty follicle
syndrome” [3, 4]. The incidence of oocyte retrieval failure,
involving a minimum ovarian hyperstimulation protocols article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Table 1 Patient characteristics
No. of cycles, n 744
No. of patients, n 361
Age, years 37 (23–46)a
Gravida per patient, n 0 (0–7)a
Parity per patient, n 0 (0–4)a
BMI, kg/m2 21 (16–36)a
Infertility period, years 6 (0–18)a
Previous treatment cycles, n 2 (1–16)a
Cycles with GnRH agonist long/all cycles (%) 509/744 (68.4)
Cycles with GnRH antagonist/all cycles (%) 235/744 (31.6)
Duration of hMG/rFSH, days 11 (7–21)a
Dose of hMG/rFSH, IU 1425 (150–4800)a
Hormone levelsb
FSH, mIU/ml 13.5 (3.2–113.5)a
LH, mIU/ml 2.4 (0.1–45.3)a
PRL, ng/ml 30.4 (0.6–314)a
Estradiol, pg/ml 1633 (62–15,768)a
Progesterone, ng/ml 0.75 (0.05–10.9)a
Endometrial thicknessb, mm 10.9 (4.6–21.2)a
No. of follicles over 15.5 mmb, n 4 (1–16)a
aMedian (range). bValues on the day of hCG injection. BMI: body mass index;
GnRH: gonadotropin-releasing hormone; hMG: human menopausal gonadotropin;
rFSH: recombinant follicle stimulating hormone; IU: international unit; LH:
luteinizing hormone; PRL: prolactin; hCG: human chorionic gonadotropin
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may cause substantial stress and anxiety for both patients
and physicians. However, the etiology of oocyte retrieval
failure remains unknown.
In the present study, we analyzed the predictive factors
for oocyte retrieval failure following controlled ovarian
hyperstimulation with GnRH agonist and GnRH antag-
onist protocols in ART programs.
Methods
This study was a retrospective cohort observational study.
A total of 744 cycles from 361 patients who underwent
in vitro fertilization (IVF) and intracytoplasmic sperm in-
jection (ICSI) programs in the period from November
2006 to November 2014 at Yamagata University Hospital,
Yamagata, Japan, were analyzed. The Yamagata University
Ethical Committee on human subjects approved the
present study, and written informed consent was obtained
from all patients.
Controlled ovarian hyperstimulation and oocyte retrieval
All patients underwent controlled ovarian hyperstimula-
tion (COH) by daily injections of human menopausal go-
nadotropin or recombinant follicle-stimulating hormone
(FSH) and pituitary desensitization following a GnRH
agonist long protocol or GnRH antagonist protocol. Cycle
monitoring was carried out using transvaginal sonography.
In the GnRH agonist long protocol, the patients received
a GnRH agonist (Suprecure nasal spray, 600 or 900 μg
daily, Mochida, Tokyo, Japan) from the mid-luteal phase
of the previous cycle to the day of human chorionic
gonadotropin (hCG) injection. In the GnRH antagonist
protocol, the patients received a GnRH antagonist (Setro-
tide, 0.25 mg daily, Merck Serono, Tokyo, Japan), which
was administered when the leading follicle was 13 to
14 mm in a diameter or on cycle day 8 and continued
until the day of hCG injection. Cumulus oocyte complexes
(COCs) were aspirated without flushing 36 h after hCG
injection using an 18- or 19-gauge needle guided by
transvaginal ultrasonography. The collected COCs were
counted and subsequently inseminated using either
conventional IVF or ICSI.
Hormone assays
Hormone measurements were performed on the day of
hCG injection. Hormone concentrations were quantified
using commercially available immunoassay kits.
Luteinizing hormone (LH), FSH, and prolactin (PRL)
were measured using an electrochemiluminescence im-
munoassay (ECLusys reagent LH, FSH, PRL kit; Roche
Diagnostics, Inc., Tokyo, Japan). Estradiol and progester-
one levels were measured using a chemiluminescence
immunoassay (Architect estradiol and progesterone kit;
Abbott Japan, Inc., Tokyo, Japan). Reliability criteria forall assays were established. The interassay coefficient of
variation was 3.3 % for estradiol and 7.9 % for progesterone.
The intraassay coefficient of variation was 5.2 % for estra-
diol and 7.2 % for progesterone. All samples were assayed
in duplicate.
Statistical analysis
We compared various possible factors affecting oocyte
retrieval between patients with zero oocytes retrieved
and those from whom one or more oocytes were
retrieved. Data are presented as mean ± SD if a normal
distribution was expected; otherwise, median and range
were used. In univariate analysis, differences in nominal
variables between the groups were compared using the
χ2 test, unless the expected frequency was < 5, in which
case Fisher’s exact probability test was used. Continuous
variables were analyzed using nonparametric Mann–
Whitney U test. In the multivariate analysis, multilevel
multivariate logistic regression models were used to
determine the independent prognostic factors for oocyte
retrieval failure. The first level was defined as the cycle
and the second level was defined as the patient. This
approach permitted analyses at the cycle level while
adjusting for within-patient correlations [5]. The area
under the receiver operating characteristic (ROC) curve
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tic models. All statistical analyses were performed using
Stata software version 13.1 (Stata Corp LP, College
Station, TX, USA). All tests for significance were two-
tailed, and significance was defined as p < 0.05.
Results
The clinical characteristics of the patients are summarized
in Table 1. The results of the univariate analyses of cycles
with zero oocytes retrieved and cycles with one or more
oocytes retrieved are shown in Table 2. Zero oocytes were
retrieved in 38 cycles (5.1 % of cycles). The number of
patients with zero oocytes retrieved was 34 (9.4 % of pa-
tients), because four patients experienced repeated oocyte
failure. Both age and parity of the cycles with zero oocytes
retrieved were significantly higher than those of the cycles
with one or more oocytes retrieved. The rate of oocyte
retrieval failure in cycles with GnRH antagonist protocol
(8.1 %) was significantly higher than that in cycles with
GnRH agonist long protocol (3.7 %). Levels of FSH and
LH were significantly higher in cycles with zero oocytes
retrieved than in those with one or more oocytes
retrieved. Levels of PRL, estradiol, and progesterone were
significantly lower in cycles with zero oocytes retrieved
than in those with one or more oocytes retrieved. TheTable 2 Univariate analysis of variables in the cycles with one or mo
Oocyte retrieval (+)
No. of cycles/all cycles (%) 706/744 (94.9)
Age, years 37 (23–46)a
Gravida per patient, n 0 (0–7)a
Parity per patient, n 0 (0–3)a
BMI, kg/m2 21 (16–36)a
Infertility period, years 6 (0–18)a
Previous treatment cycles, n 2 (1–16)a
No. of cycles with GnRH
agonist long/no. of cycles (%)
190/706 (69.4)
No. of cycles with GnRH
antagonist/no. of cycles/ (%)
216/706 (30.6)
Duration of hMG/rFSH, days 11 (7–21)a
Dose of hMG/rFSH, IU 1425 (150–4800)a
Hormone levelsb
FSH, mIU/ml 13.4 (3.2–113.5)a
LH, mIU/ml 2.3 (0.1–26.8)a
PRL, ng/ml 30.7 (0.6–314)a
Estradiol, pg/ml 1717 (88–15,768)a
Progesterone, ng/ml 0.77 (0.05–10.9)a
Endometrial thicknessb, mm 10.9 (4.6–21.2)a
No. of follicles over 15.5 mmb, n 4 (1–16)a
aMedian (range). bValues on the day of hCG injection. BMI: body mass index; GnRH:
rFSH: recombinant follicle stimulating hormone; IU: international unit; LH, luteinizingnumber of follicles over 15.5 mm on the day of hCG injec-
tion was significantly lower in cycles with zero oocytes re-
trieved than in those with one or more oocytes retrieved.
On multilevel multivariate logistic analysis, GnRH an-
tagonist protocol (odds ratio [OR] 3.06, 95 % confidence
interval [CI] 1.058.96, P = 0.04), estradiol level on the
day of hCG injection (OR 0.997, 95 % CI 0.9960.998,
P = 0.001), and LH level on the day of hCG injection
(OR 1.19, 95 % CI 1.061.33, P = 0.003) were independent
predictive factors for oocyte retrieval failure (Table 3).
As these parameters appeared important for predicting
oocyte retrieval failure, we compared the levels of
estradiol and LH in cycles with GnRH agonist long and
GnRH antagonist protocols (Fig. 1). Although the
median level of estradiol on the day of hCG injection in
cycles with zero oocytes retrieved was significantly lower
than that in cycles with one or more oocytes retrieved,
the median levels of LH on the day of hCG injection did
not significantly differ between cycles with zero and one
or more oocytes retrieved in cycles with GnRH agonist
long protocol (Fig. 1a). By contrast, whereas the level of
estradiol on the day of hCG injection in the cycles with
zero oocytes retrieved was significantly lower than that
in cycles with one more oocytes retrieved, the level of
LH on the day of hCG injection in the cycles with zerore oocytes retrieved and zero oocytes retrieved



















gonadotropin-releasing hormone; hMG: human menopausal gonadotropin;
hormone; PRL, prolactin; hCG: human chorionic gonadotropin
Table 3 Multilevel multivariate logistic analysis for oocyte
retrieval failure




Estradiol on the day
of hCG injection
0.997 0.996–0.998 0.0001
LH on the day of
hCG injection
1.19 1.06–1.33 0.003
GnRH: gonadotropin releasing hormone; hCG: human chorionic gonadotropin;
LH: luteinizing hormone
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the cycles with one or more oocytes retrieved in cycles
with GnRH antagonist protocol (Fig. 1b).
Next, we validated the efficacy of the levels of estradiol
and LH on the day of hCG injection in predicting the
possibility of oocyte retrieval failure. Figure 2 shows the
ROCs of estradiol and LH for the prediction of oocyte
retrieval failure. In all cycles, the areas under the curve
(AUCs) for estradiol and LH were 0.84 and 0.63, respect-
ively. In cycles with GnRH agonist long protocol, theFig. 1 Levels of estradiol and LH on the day of hCG injection in patients w
cycles with zero and one or more oocytes retrieved. a. levels of estradiol an
protocol. b. levels of estradiol and LH on the day of hCG injection in cyclesAUCs for estradiol and LH were 0.84 and 0.52, respect-
ively. In cycles with GnRH antagonist protocol, the AUCs
for estradiol and LH were 0.81 and 0.82, respectively.
Table 4 summarizes the sensitivities, specificities, and
positive and negative predictive values for predicting oo-
cyte retrieval failure at various thresholds for estradiol and
LH levels in all cycles, cycles with GnRH agonist long
protocol, and cycles with GnRH antagonist protocol.
Discussion
We evaluated the predictive factors for oocyte retrieval
failure with controlled ovarian hyperstimulation proto-
cols in ART treatment cycles. The independent predictive
factors for oocyte retrieval failure on multilevel multivari-
ate analysis were use of the GnRH antagonist protocol
and levels of estradiol and LH on the day of hCG injec-
tion. Analyses of ROCs revealed that estradiol level was
more predictive of oocyte retrieval failure than LH level
on the day of hCG injection in all treatment cycles,
whereas estradiol and LH levels demonstrated similar
predictive power for oocyte retrieval failure in cycles with
GnRH antagonist protocol.ho underwent GnRH agonist long and GnRH antagonist protocols in
d LH on the day of hCG injection in cycles with GnRH agonist long
with GnRH antagonist protocol
Fig. 2 Receiver operating characteristic (ROC) curves of estradiol and LH on the day of hCG injection. ROC curves of estradiol and LH on the day
of hCG injection in the cycles with all, GnRH agonist long, and GnRH antagonist protocols for predicting oocyte retrieval failure
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oocyte retrieval failure with the GnRH antagonist proto-
col was three times that of the GnRH agonist long
protocol. There have been no previous studies compar-
ing types of COH in cycles with oocyte retrieval failure.
The number of oocytes retrieved in cycles with GnRH
antagonist protocol tends to lower than that in cycles
with GnRH agonist long protocol [6, 7]. The etiology of
the higher incidence of oocyte retrieval failure in cycles
with GnRH antagonist protocol remains unclear. As the
level of LH on the day of hCG injection was significantly
higher in cycles with oocyte retrieval failure, insufficient
LH suppression in the GnRH antagonist protocol might
be a cause of oocyte retrieval failure.
A lower level of estradiol demonstrated positive predict-
ive value for oocyte retrieval failure. Baum et al. reported
that lower estradiol level on the day of hCG injection was
a risk factor for oocyte retrieval failure in ART treatment
cycles with controlled ovarian hyperstimulation protocols
[8]. In the present study, the median level of estradiol in
cycles with oocyte retrieval failure was three times greater
than that in cycles with one or more oocytes retrieved.
Previous studies also reported that lower estradiol level on
the day of hCG injection was a risk factor for oocyteTable 4 Predictive efficacy of estradiol and LH levels on the day of
Type of COH Threshold value
All cycles Estradiol 1080 pg/ml
LH 3.8 mIU/ml
Cycles with GnRH agonist long Estradiol 887 pg/ml
LH 10.9 mIU/ml
Cycles with GnRH antagonist Estradiol 1040 pg/ml
LH 1.7 mIU/ml
COH: controlled ovarian hyperstimulation; PPV: positive predictive value; NPV: nega
hormoneretrieval failure in ART treatment cycles with COH [9,
10]. The etiology of lower estradiol level on the day of
hCG injection might be poor follicle development. In fact,
we observed a lower number of developing follicles in
cycles with oocyte retrieval failure compared to cycles
with one or more oocytes retrieved.
Higher LH level on the day of hCG injection was also a
positive predictor for oocyte retrieval failure. Choi et al.
reported that the cancellation rate of ART treatment
cycles was greater in cases of higher LH levels on the day
of hCG injection than in cases of lower LH levels [11].
Premature LH surge results in cancellation of IVF treat-
ment cycles or developmental arrest of oocytes because of
early luteinization of immature follicles before oocyte re-
trieval [12–14]. Taken together, these results suggest that
insufficient LH suppression during COH and fewer devel-
oping follicles might be a cause of oocyte retrieval failure.
Several candidates for the etiology of oocyte retrieval
failure in ART treatment cycles have been proposed. First,
the low bioavailability of hCG is one possible etiology of
oocyte retrieval failure [15–17]. Zegers-Hochschild et al.
reported that low bioavailability of hCG may be linked to
intrinsic defects in the in vivo biological activity of some
batches of hCG [15]. In the present study, the patientshCG injection for oocyte retrieval failure
Sensitivity Specificity PPV NPV
0.71 0.84 0.19 0.98
0.71 0.53 0.07 0.97
0.81 0.74 0.14 0.99
0.96 0.21 0.06 0.99
0.64 0.90 0.24 0.98
0.60 0.95 0.37 0.98
tive predictive value; LH: luteinizing hormone; GnRH: gonadotropin-releasing
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batches may have differed during the study period. There-
fore, problems with the hCG drug might be a cause of oo-
cyte retrieval failure. Reduced follicle development during
COH is another possible etiology of oocyte retrieval failure
[18]. Patients with a poor response to COH are vulnerable
to oocyte retrieval failure [3, 7–9, 18]. These patients are
considered to have a diminished ovarian reserve mainly
due to ovarian aging [3, 9, 10]. In the present study,
patient age was significantly higher in cycles with oocyte
retrieval failure than those in which one or more oocytes
were retrieved. Because we did not measure FSH levels at
the early follicular phase or anti-Müllerian hormone, it is
possible that patients with oocyte retrieval failure were
subject to diminished ovarian reserve. The final possible
etiology of oocyte retrieval failure is human error, such as
a missed and/or incorrect dose of hCG injection [18–20].
We did not exclude possible cases of oocyte retrieval fail-
ure caused by human errors, such as a missed and/or in-
correct dose of hCG injection.
When interpreting our results, the strengths and limi-
tations of our study must be considered in light of its
retrospective cohort design. There were potential con-
founding factors that should be acknowledged. In the
present study, in univariate analysis, the patients’ age
and parity were significantly higher in the cycles with
zero oocytes retrieved than those of the cycles with one
or more oocytes retrieved. To eliminate confounding
factors, we applied multilevel multivariate analysis to de-
termine the predictive factors for oocyte retrieval failure.
As a result, age and parity were eliminated as candidate
predictive factors for oocyte retrieval failure. However,
because of its small sample size, the findings of the
current study are vulnerable to type II error [21]. A
larger-scale study is needed to evaluate the predictive
factors for oocyte retrieval failure with COH in ART
treatment cycles.Conclusions
Our results suggest that GnRH antagonist protocol,
lower level of estradiol, and higher level of LH on the
day of hCG injection might be positive predictors for
oocyte retrieval failure. These findings provide useful in-
formation to both patients and physicians for developing
better COH protocols in ART programs.Abbreviations
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